Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension
Lauren Brash, Gareth D Barnes, Melanie J Brewis, A Colin Church, Simon J Gibbs, Luke S G E Howard, Geeshath Jayasekera, Martin K Johnson, Neil McGlinchey, Joelle Onorato, Joanne Simpson, Colin Stirrat, Stephen Thomson, Geoffrey Watson, Martin R Wilkins, Carrie Xu, David J Welsh, David E Newby, Andrew J Peacock, Lauren Brash, Gareth D Barnes, Melanie J Brewis, A Colin Church, Simon J Gibbs, Luke S G E Howard, Geeshath Jayasekera, Martin K Johnson, Neil McGlinchey, Joelle Onorato, Joanne Simpson, Colin Stirrat, Stephen Thomson, Geoffrey Watson, Martin R Wilkins, Carrie Xu, David J Welsh, David E Newby, Andrew J Peacock
Abstract
Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models. Here, the authors examined the short-term pulmonary hemodynamic effects of systemic apelin infusion in patients with PAH. In a double-blind randomized crossover study, 19 patients with PAH received intravenous (Pyr1)apelin-13 and matched saline placebo during invasive right heart catheterization. (Pyr1)apelin-13 infusion caused a reduction in pulmonary vascular resistance and increased cardiac output. This effect was accentuated in the subgroup of patients receiving concomitant phosphodiesterase type 5 inhibition. Apelin agonism is a novel potential therapeutic target for PAH. (Effects of Apelin on the Lung Circulation in Pulmonary Hypertension; NCT01457170).
Keywords: APJ; CO, cardiac output; FA, formic acid; NO, nitric oxide; PAEC, pulmonary artery endothelial cells; PAH, pulmonary arterial hypertension; PDE5, phosphodiesterase-5; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance; apelin; human; pulmonary arterial hypertension.
Figures
References
- Morrell N.W., Adnot S., Archer S.L. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S20–S31.
- NHS Digital. Fifth Annual Report: Key Findings From the National Audit of Pulmonary Hypertension of the United Kingdom, Channel Islands, Gibraltar and Isle of Man. Health and Social Care Information Centre; Leeds, UK: 2015. pp. 1–38.
- Tatemoto K., Hosoya M., Habata Y. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471–476.
- Kleinz M.J., Skepper J.N., Davenport A.P. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005;126:233–240.
- Salcedo A., Garijo J., Monge L. Apelin effects in human splanchnic arteries. Role of nitric oxide and prostanoids. Regul Pept. 2007;144:50–55.
- Ashley E., Powers J., Chen M. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovas Res. 2005;65:73–82.
- Lee D.K., Cheng R., Nguyen T. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000;74:34–41.
- Tatemoto K., Takayama K., Zou M.X. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;99:87–92.
- Cheng X., Cheng X.S., Pang C.C.Y. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol. 2003;470:171–175.
- Berry M.F., Pirolli T.J., Jayasankar V. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation. 2004;110 Suppl 1:II187–II193.
- Japp A.G., Cruden N.L., Amer D.A.B. Vascular effects of apelin in vivo in man. J Am Coll Cardiol. 2008;52:908–913.
- Barnes G.D., Alam S., Carter G. Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ Heart Fail. 2013;6:482–491.
- Japp A.G., Cruden N.L., Barnes G. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation. 2010;121:1818–1827.
- Falcao-Pires I., Goncalves N., Henriques-Coelho T., Moreira-Goncalves D., Roncon-Albuquerque R., Leite-Moreira A.F. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2009;296:H2007–H2014.
- Alastalo T.P., Li M., de Jesus Perez V. Disruption of PPARγ/β-catenin–mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest. 2011;121:3735–3746.
- Jing Z.C., Jiang X., Han Z.-Y. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J. 2009;33:1354–1360.
- Sulica R., Dinh H.V., Dunsky K., Fuster V., Poon M. The acute hemodynamic effect of IV nitroglycerin and dipyridamole in patients with pulmonary arterial hypertension: comparison with IV epoprostenol. Congest Heart Fail. 2005;11:139–144. quiz 145–6.
- Petkov V., Ziesche R., Mosgoeller W. Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax. 2001;56:734–736.
- Apostolopoulou S.C., Rammos S., Kyriakides Z.S. Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease. Heart. 2003;89:1221–1226.
- Grimminger F., Weimann G., Frey R. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J. 2009;33:785–792.
- Voswinckel R., Reichenberger F., Gall H. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm Pharmacol Ther. 2009;22:50–56.
- McLaughlin V.V., Gaine S.P., Howard L.S. Treatment goals of pulmonary hypertension. J Am Coll Cardiol. 2013;62 Suppl:D73–D81.
- Machado R.D., Eickelberg O., Elliott C.G. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S32–S42.
- Dai T., Ramirez-Correa G., Gao W.D. Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol. 2006;553:222–228.
- Brame A.L., Maguire J.J., Yang P. Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertension. 2015;65:834–840.
Source: PubMed